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INDRODUCTION 
INTRODUCTION: 
Modern pharmaceutical technology is concentrated on new drug forms which 
are targeted to the exact site at the appropriate time, with maximum efficiency and 
with reduced side-effects. Therapeutic effectiveness of a drug depends upon the 
bioavailability and ultimately upon the solubility of drug molecules. Solubility is one 
of the important parameter to achieve desired concentration of drug in systemic 
circulation for pharmacological response to be shown. According to recent estimates, 
nearly 40% of new chemical entities are rejected because of poor solubility i.e. 
biopharmaceutical properties.[1]  
The solubility properties of drugs and the dissolution of the active substance 
from dosage forms have a basic impact on the bioavailability of the product. 
Enhancement of the solubility of poorly-soluble drug substances is one of the most 
important tasks in pharmaceutical formulation development.[2] The drug substances 
are categorized into four classes based on their solubility parameter and permeability 
to bio-membranes, and such a classification system is called as a Biopharmaceutical 
Classification System (BCS). The BCS guidance takes into account three major 
factors, dissolution, solubility, and intestinal permeability, which govern the rate and 
extent of drug absorption from immediate release solid dosage forms. The concept of 
BCS provides a better understanding of the relationship between drug release from the 
product and the absorption process. [3] 
 
BIOPHARMACEUTICAL CLASSIFICATION OF DRUGS (BCS):  
The BCS is a scientific framework for classifying a drug substance based on 
its aqueous solubility and intestinal permeability [4]. It allows for the prediction of in-
vivo pharmacokinetics for oral immediate release (IR) drug products by classifying 
drug compounds into four classes. The in-vivo performance of orally administered 
drugs depends upon their solubility and tissue permeability characteristics. The 
release rate or solubility of the drug substance will not be a governing parameter if the 
absorption of the drug is permeation rate limited and in such cases the in-vitro 
dissolution study can be used to demonstrate the bioavailability (BA) or 
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bioequivalence (BE) of the drug product through in vitro - in vivo correlation 
(IVIVC). 
Class Solubility Permeability 
I High High 
II Low High 
III High Low 
IV Low Low 
Table No 1:BCS classification of Drugs 
Class-I Drugs: 
 The drugs of this class exhibit high absorption number and high dissolution 
number. These compounds are well absorbed, and their absorption rate is usually 
higher than the excretion rate. In in-vivo, these drugs behave like an oral solution 
having fast dissolution and rapid bioavailability. Since the dissolution and absorption 
of class I drugs is very fast, bioavailability and bioequivalence are unnecessary for the 
products of such drugs. These drugs are good candidates for controlled drug delivery 
if they qualify pharmacokinetically and pharmacodynamically for the purpose. Gastric 
emptying is often the rate governing parameter in this case. Examples include 
Metoprolol, Diltiazem, Verapamil, Propanolol etc.. [5] 
Class-II Drugs:  
The drugs of this class have a high absorption number but a low dissolution 
number. In-vivo drug dissolution is then a rate limiting step for absorption except at a 
very high dose number. Drugs belonging to this class have low solubility and high 
permeability, hence, the dissolution rate becomes the governing parameter for 
bioavailability. In-vitro - in-vivo correlation (IVIVC) is usually accepted for this class 
of drugs. The bioavailability of these products is limited by their salvation rates. 
Hence, a correlation between the in-vivo bioavailability and the in-vitro salvation can 
be found. These drugs exhibit variable bioavailability and need enhancement in the 
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dissolution rate by different methods ( These are also suitable for controlled release 
development. Examples include Gibenclamide, Phenytoin, Danazol, Mefenamic acid. 
Class-III Drugs:  
Permeation through the intestinal membrane forms the rate-determining step 
for these drugs. Since absorption is permeation rate limited, bioavailability is 
independent of drug release from the dosage form. For example, the various ranitidine 
products having different dissolution profiles produce super imposable plasma 
concentration versus time profile in-vivo. These drugs generally exhibit low 
bioavailability and permeability enhancement is generally required. These drugs are 
problematic for controlled release development. [5] 
 Class-IV Drugs:  
Drugs of this class exhibit poor and variable bioavailability. The overall 
bioavailability is governed by several factors such as rate of dissolution, intestinal 
permeability, gastric emptying, and so on. These drugs are generally not suitable for 
oral drug delivery or else some special drug delivery technologies such as 
nanosuspensions will be needed. Examples include Hydrochlorothiazide, Taxol, 
Frusemide.amples include Cimetidine, Ranitidine, Cyclovir, Neomycin B etc.[5] 
SOLUBILITY AND DISSOLUTION:  
Solubility is a physicochemical property of a substance that can be generally 
defined as the highest amount of a substance that can be dissolved in a solvent, at a 
constant temperature and pressure.More specifically, solubility is considered to be the 
concentration that a solute reaches in a solution when equilibrium exists between the 
solid phase and the solution phase (saturated solution) at a defined temperature and 
pressure.[6] 
Dissolution is the process by which a substance becomes dissolved in a 
solvent. Dissolution takes place when a solid substance comes in contact with 
molecules of a compatible solvent. [7] 
Due to this major reason Solubility enhancement is one of the important 
parameters which should be considered in formulation development of orally 
administered drug with poor aqueous solubility [8]. Solubility is the characteristic 
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The solubility of a solute is the maximum quantity of solute that can dissolve in a 
certain quantity of solvent or quantity of solution at a specified temperature. [11] 
Importance of Solubility  
The major challenge with the design of oral dosage forms lies with their poor 
bioavailability. The oral bioavailability depends on several factors including aqueous 
solubility, drug permeability, dissolution rate, first-pass metabolism, presystemic 
metabolism, and susceptibility to efflux mechanisms. The most frequent causes of low 
oral bioavailability are attributed to poor solubility and low permeability. [12].  
Solubility is one of the important parameters to achieve desired concentration 
of drug in systemic circulation for achieving required pharmacological response [13]. 
Poorly water soluble drugs often require high doses in order to reach therapeutic 
plasma concentrations after oral administration. Low aqueous solubility is the major 
problem encountered with formulation development of new chemical entities as well 
as generic development. Any drug to be absorbed must be present in the form of an 
aqueous solution at the site of absorption. Water is the solvent of choice for liquid 
pharmaceutical formulations. Most of the drugs are either weakly acidic or weakly 
basic having poor aqueous solubility. More than 40% NCEs (new chemical entities) 
developed in pharmaceutical industry are practically insoluble in water. These poorly 
water soluble drugs having slow drug absorption leads to inadequate and variable 
bioavailability and gastrointestinal mucosal toxicity. For orally administered drugs 
solubility is the most important one rate limiting parameter to achieve their desired 
concentration in systemic circulation for pharmacological response. Problem of 
solubility is a major challenge for formulation scientist [14]. The improvement of 
drug solubility thereby its oral bioavailability remains one of the most challenging 
aspects of drug development process especially for oral-drug delivery system. There 
are numerous approaches available and reported in literature to enhance the solubility 
of poorly water-soluble drugs. The techniques are chosen on the basis of certain 
aspects such as properties of drug under consideration, nature of excipients to be 
selected, and nature of intended dosage form. The poor solubility and low dissolution 
rate of poorly water soluble drugs in the aqueous gastrointestinal fluids often cause 
insufficient bioavailability. Especially for class II (low solubility and high 
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4. Temperature:  
Solubility affected by temperature. If the solution process absorbs energy then 
the solubility will increase with increasing temperature. If the solution process 
releases energy then the solubility will decrease with increasing temperature. [21] 
5. Pressure: 
For solids and liquid solutes, solubility not affected by change in pressure but 
for gaseous solutes, solubility increases as pressure increases and decrease as pressure 
decrease[22]. 
 
TECHNIQUES TO OVERCOME POOR SOLUBITY 
The description of a technology as ‘solubility enhancing’ can be misleading, 
since although the phenomenon of super-saturation is real, the techniques used do not 
increase the solubility of insoluble compounds. More accurately, they present the drug 
in a form which is optimal to its absorption, given its solubility limitations. It is also 
important to be aware that water solubility also requires the specification of 
temperature and pH; many important drugs only exhibit aqueous solubility under 
certain physiological conditions, and these need to be met at the site of absorption 
[23]. 
The techniques that are used to overcome poor drug solubility are discussed 
below  
I. Chemical Modifications: 
1. Salt Formation 
2. Co-crystallization 
3. Co-solvency 
4. Hydrotropic 
5. Solublizing agent 
6. Nanotechnology 
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II. Physical Modifications : 
1. Particle size reduction 
a. Micronization 
b. Nanosuspension 
2. Modification of the crystal habit 
a.Polymorphs 
b.Pseudopolymorphs 
3.Complexation 
a.Use of complexing agents 
4.Solubilization by surfactants: 
a.Microemulsions 
b.Self microemulsifying drug delivery system 
5.Drug dispersion in carriers 
a.Solid dispersions 
b.Solid solutions 
 
I. CHEMICAL MODIFICATIONS 
1.Salt Formation : 
Salt formation is the most common and effective method of increase solubility 
and dissolution rates of acidic and basic drugs. Acidic or basic drug converted into 
salt having more solubility than respective drug. Ex. Aspirin, Theophylline, 
Barbiturates[24]. 
2. Co-crystallisation : 
The  new approach available for the enhancement of drug solubility is through 
the application of the co-crystals, it is also referred as molecular complexes. A Co-
crystals may be defined as crystalline material that consist of two or more molecular 
(& electrical neutral) species held together by non-covalent forces. It can be prepared 
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by evaporation of a heteromeric solution or by grinding the components together or 
by sublimation, growth from the melt & slurry preparation. It is increasingly 
important as an alternative to salt formation, particularly for neutral compounds[25]. 
 
3. Co-solvent : 
 It is well-known that the addition of an organic cosolvent to water can 
dramatically change the solubility of drugs. Weak electrolytes and nonpolar 
molecules have poor water solubility and it can be improved by altering polarity of 
the solvent. Solvent used to increase solubility known as cosolvent. It is also 
commonly referred to as solvent blending[26]. 
 
4. Hydrotropy :  
It designate to increase in solubility in water due to presence of large amount 
of additives. It improves solubility by complexation involving weak interaction 
between hydrophobic agents (Sodium benzoate, sodium alginate, urea) & solute. Ex. 
Sublimation of Theophylline with Sodium acetate & Sodium alginate[27]. 
 
5. Solublising Agents : 
The solubility of poorly soluble drug can also be improved by various 
solubilizing materials. Ex. PEG 400 is improving the solubility of 
hydrochlorthiazide[28]. 
 
6. Nanotechnology Approaches : 
 Nanotechnology will be used to improve drugs that currently have poor 
solubility. Nanotechnology refers broadly to the study and use of materials and 
structures at the nanoscale level of approximately 100 nanometers (nm) or less. For 
many new chemical entities of very low solubility, oral bioavailability enhancement 
by micronisation is not sufficient because micronised product has very low effective 
surface area for dissolution and next step taken was nanonisation[29]. 
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II. PHYSICAL MODIFICATIONS 
1.Particle Size Reduction : 
 The techniques of size reduction using various milling processes are well 
established and these practices are a standard part of formulation development8. This 
can be done mainly by Micronization & Nanosuspension9. As particle size decreases, 
surface area of particle increases resulting in increase in solubility. Sometimes  
nanocrystallisation technique is also used for particle size reduction [30]. 
 
2.Modification of Crystal Habit: 
 Polymorphism is the ability of an element or compound to crystallize in more 
then one crystalline form. Different polymorphs of drugs are chemically identical, but 
they exhibit different physicochemical properties including solubility, melting point, 
density, texture, stability. Similarly amorphous form of drug is always more suited 
than crystalline form due to higher energy associated & increase in surface area. 
Order for dissolution of different solid forms of drug[31]. 
Amorphous >Metastable polymorph >Stable polymorph 
 
3. Complexation : 
 Complexation is the association between two or more molecules to form a 
non bonded entity with a well defined stichiometry. Complexation relies on relatively 
weak forces such as London forces, hydrogen bonding and hydrophobic 
interactions7,12. Examples of complexaing agents are; chelates- EDTA, EGTA, 
molecular complexes- polymers, inclusion complexes cyclodextrins[32]. 
 
4. Solublisation By Surfactents : 
 Surfactants are molecules with distinct polar and nonpolar regions. Most 
surfactants consist of a hydrocarbon segment connected to a polar group. The polar 
group can be anionic, cationic, or nonionic. When small polar molecules are added 
they can accumulate in the hydrophobic core of the micelles[33]. This process of 
solubilization is very important in industrial and biological processes. The presence of 
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surfactants may lower the surface tension but increases solubility of drug within an 
organic solvent. 
 
Methods for enhancing the Solubility & dissolution of class II drugs: 
• Buffering the pH of microenvironment  
• Use of salts of weak acids and weak bases  
• Use of solvates and hydrates  
• Use of selected polymorphic forms  
• Complexation  
• Prodrug approach  
• Use of surfactants 
 
POLYMORPHISM: 
The relevance of polymorphism to the pharmaceutical industry is mainly to 
determine which form of a given API is the most stable for a particular 
pharmaceutical dosage form. Different crystalline polymorphs and solvates have 
different crystal packing, molecular conformation and lattice energy. 
These result in differences in the physico-chemical properties of a drug, for 
instance density, hardness, tabletability, melting point, heat of fusion, solubility and 
dissolution rates. The differences in physical properties affect the preparation of drugs 
in dosage forms. Because of all these differences, it is important to understand the 
solid state properties of polymorphic forms, as well as understand polymorphism, in 
order to gain control over the crystallisation process. This knowledge helps enable the 
researcher to obtain a specific stable polymorphic form, suitable for a specific dosage 
form. 
Polymorphism can be classified into two different categories, because of their 
differences in thermodynamic properties.  Enantiotropes can reversibly transit 
between different polymorphs at a certain transition temperature below the melting 
point, while this is not possible for monotropes. [34] 
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SOLVATES: 
It is important to note that crystalline solids exist in different forms and the 
three types of crystalline solids comprise polymorphs, solvates and hydrates. 
Solvates are characterised as crystalline structures that contain solvent 
molecules, which cause significant differences in the physico-chemical properties of a 
drug. Solvates and crystalline solids have different molecular conformation and 
packing, hence different physical properties, such as melting points, dissolution rates, 
solubility, thermodynamic and kinetic properties. Solubility differences can impact on 
the absorption of these compounds. 
Desolvated solvates are unsolvated compounds. These solvates have no 
distinctive crystalline form and therefore the molecules are not structured like their 
crystalline counterparts There are different ways for a solvent to interact with a 
crystalline solid:   
• The solvent molecules can form weak interactions, namely van der 
Waals, dipole-dipole, or hydrogen bonding; 
• The physical entrapment of the solvent in the growing crystal; and 
• The adsorbing of solvent in a disordered manner in different regions of 
the crystal. 
The different crystal faces of a substance have different affinities, therefore the 
amount of solvent or water absorbed in crystalline materials depends on their 
morphology and also on many other parameters. The solvent can also be physically 
entrapped in a crystal, called liquid inclusion. Large amounts of solvent may be 
adsorbed on the surface of the crystal, which can cause problems with grinding and 
granulation of these solvates. In an amorphous state the molecular entities are packed 
more closely, resulting in stronger intermolecular interactions and providing no space 
for solvent intake. Compounds can crystallise and bind with the solvent to form a 
solvate, in which case the solvent is a part of the crystalline structure Solvates can be 
divided into two categories, namely 
• Stoichiometric solvates 
• Nonstoichiometric solvates 
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Stoichiometric solvates are known as molecular compounds and the solvent is 
a part of the crystalline structure. The desolvation of a stoichiometric solvate usually 
results in a different crystalline structure, or leads to a disordered or amorphous state. 
Nonstoichiometric solvates are inclusion compounds and the solvent is 
usually captured in channels of the crystalline structure. These solvates have large, 
awkward, crystal shapes, which cannot pack close together.  
The ability of a solvate to form or to desolvate has a significant impact on the 
phase stability of these structures, because it is different for every form. The stability 
of solvates also depends on the temperatures and the partial pressure of the solvent. 
The formation of solvates is best when the crystallisation takes place at lower 
temperatures. The partial pressure of solvates also becomes practically zero for 
solvates with organic solvents, but not for hydrates, because of the atmospheric 
moisture. Stability depends on many factors, including the size of the crystals, crystal 
defects, dynamics of the atmosphere and the desolvation mechanism. To characterise 
and determine the stability of solvates, thermogravimetric analysis, like differential 
scanning calorimetry (DSC) can be used, because it analyses the thermal stability at 
dry atmospheric conditions, whilst it can be done at elevated humidity. The stability 
range of solvated and unsolvated forms can be determined through solubility studies 
at different temperatures. This is also used to determine the transition temperature 
between the different phases of the solvate .[34] 
  
HYDRATES: 
When a crystalline structure or compound is combined with water or a water 
element, this solvent is called a hydrate. It is easy for most pharmaceutical substances 
to form crystalline hydrates, since water is a small molecule that is capable of forming 
hydrogen bonds in multiple directions. This small molecule can also easily fill voids 
within the molecular packing of a solid. Water can therefore combine drug molecules 
in structured crystalline forms. It is important to note that the activity of water in a 
medium is the only reason why a hydrate structure will form. A monohydrate is a 
compound that contains one water molecule, whereas a dihydrate contains two water 
molecules. According to hydrates are characterised in three different categories: 
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 Isolated site hydrates: Water molecules in this compound are isolated from 
others by combining with drug molecules, e.g. cephradine dihydrate; 
Channel hydrates: Water molecules lie next to others and form channels 
through the crystal, e.g. ampicillin trihydrate. 
Ion-associated hydrates: Metal ions are combined with water, e.g. calteridol 
calcium. 
Phase changes can occur, for example when a hydrated compound converts 
into an amorphous phase, because of dehydration. This can cause a poorly soluble 
drug to convert into a compound that is much more soluble, whilst impacting 
negatively on the stability. Humidity, temperature and pressure can cause such phase 
changes.[35] 
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LITERATURE REVIEW 
 
Ketan T.et al., Drug Solubility: Importance and Enhancement Techniques. 
Solubility, the phenomenon of dissolution of solute in solvent to give a homogenous 
system, is one of the important parameters to achieve desired concentration of drug in 
systemic circulation for desired (anticipated) pharmacological response. Low aqueous 
solubility is the major problem encountered with formulation development of new 
chemical entities as well as for the generic  development. Various techniques are used 
for the enhancement of the solubility of poorly soluble drugs which include physical 
and chemical modifications of drug and other methods like particle size reduction, 
crystal engineering, salt formation, solid dispersion, use of surfactant, complexation, 
and so forth. Selection of solubility improving method depends on drug property, site 
of absorption, and required dosage form characteristics. .[36] 
Mohini S.Patil1 et al., Solubility enhancement by various techniques: an 
overview. Solubility is not to be confused with the ability to dissolve or liquefy a 
substance, since this process may occur not only because of dissolution. But also 
because of a chemical reaction. Low aqueous solubility is the Major problem 
encountered with formulation development of new Chemical entities as well as for the 
generic development. More than 40% of new chemical entities developed in 
pharmaceutical industry are Lipophillic and fail to reach the market due to their poor 
water Solubility. The solubility behavior of drug is the major challenge for 
Formulation scientist. The present review is devoted to increase the Solubility of 
poorly water soluble drugs. .[37]. 
Marique Aucamp et al., Solution-mediated phase transformation of different 
roxithromycin solid-state forms: Implications on dissolution and solubility. The 
objective of this study was to describe the solid-state forms in which roxithromycin 
may exist and The significant influence of solution-mediated phase transformation on 
the dissolution and solubility Behavior of these forms. Roxithromycin may exist as: 
Form I (monohydrate), Form II (amorphous), Form III (anhydrate) and a mixture of 
Forms I and III. Form III and Mixture I/III have not been reported previously, 
Probably due to incomplete solid-state characterization. The Various forms differed 
 Department of Pharmaceutics  
Arulmigu Kalasalingam College of Pharmacy. Page 17 
 
 
significantly in terms of dissolution profiles, which could have a marked influence On 
bioavailability and performance of the final dosage form. It was demonstrated that 
solvent replacement, During dissolution testing, masks the characteristic profile. 
Finally, we propose that peak dissolution concentrations Should be used to give a 
more exact indication of the aqueous solubility enhancement ratio obtained With 
metastable forms of API. .[38]. 
Amit Chaudhary et al., Enhancement of solubilization and bioavailability of 
poorly soluble drugs. By physical and chemical modifications: A recent review. The 
aim of this review was to improve the solubility and bioavailability of poorly soluble 
drugs by using various approaches like physical, chemical and others modifications or 
techniques. The solubility of a solute is the maximum quantity of solute that can 
Dissolve in a certain quantity of solvent or quantity of solution at a specified 
Temperature. Solubility is one of the important parameter to achieve desired 
Concentration of drug in systemic circulation for pharmacological response to be 
shown. Drug efficacy can be severely limited by poor aqueous solubility and some 
drugs also Show side effects due to their poor solubility. There are many techniques 
which are Used to enhance the aqueous solubility.[39]. 
Jinal N. Patel et al., Techniques to improve the solubility of poorly soluble 
drugs. A drug administered in solution form immediately available for absorption and 
efficiently absorbed than the same. Amount of drug administered in a tablet or capsule 
form. Solubility is a most important parameter for the oral Bioavailability of poorly 
soluble drugs. Dissolution of drug is the rate determining step for oral absorption of 
the Poorly water soluble drugs, which can subsequently affect the in vivo absorption 
of drug. It is now possible that to increase the solubility of poorly soluble drugs with 
the help of various techniques such as Physical method, Chemical method. Co-
crystallisation, co-solvency solubilizing agents, molecular encapsulation with 
cyclodextrins, nanotechnology approaches and hydrotropy. [40]. 
Varun Raj Vemula et al., Solubility enhancement techniques Solubility is the 
phenomenon of dissolution of solid in liquid phase to give a homogenous system. 
Solubility is one of the important parameter to achieve desired concentration of drug 
in systemic circulation for pharmacological response to be shown. Water is the 
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solvent of choice for liquid pharmaceutical formulations. Most of drugs weakly acidic 
and weakly basic with poor aqueous solubility. Hence various techniques are used for 
the improvement of the solubility of poorly water-soluble drugs include 
micronization, chemical modification, ph adjustment, solid dispersion, complexation, 
co‐solvency, micellar solubilization, hydrotropy etc. The purpose of this review article 
is to describe the techniques of solubilizaton for the attainment of effective absorption 
and improved bioavailability. [41]. 
Abhijit A. Et al., reviewed the Antisolvent Crystallization of Poorly Water 
Soluble Drugs. The enhancement in bioavailability of the drugs is One of the most 
important concerning aspects of the pharmaceutical industries. Preparation of 
nanoparticles or Microparticles of these drugs is the newest formulation strategies. An 
antisolvent crystallization technique is being used to prepare nanoparticles or 
microparticles for poorly water soluble drugs at research scale. This method has an 
ability to change the solid-state properties of pharmaceutical substances including the 
modification of crystal formation and particle size distributions. Therefore, various 
operating variables and their effect on the particle size of poorly water soluble drugs 
in an anti-solvent crystallization have been reviewed. [42]. 
Abhijit A et al.,The enhancement in bioavailability of the drugs is one of the 
most important concerning aspects of the pharmaceutical industries. Preparation of 
nanoparticles or microparticles of these drugs is the newest formulation strategies. 
The size and morphology of a drug are affecting several essential pharmaceutical 
properties. In general, the drug delivery system needs narrow particle size distribution 
with regular particle shape, particularly, an engineered drug particles to meet 
biopharmaceutical and processing needs. An antisolvent crystallization technique is 
being used to prepare nanoparticles or microparticles for poorly water soluble drugs at 
research scale. This method has an ability to change the solid-state properties of 
pharmaceutical substances including the modification of crystal formation and 
particle size distributions. Therefore, various operating variables and their effect on 
the particle size of poorly water soluble drugs in an anti-solvent crystallization have 
been reviewed. [43]. 
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N.L. Prasanthi et al.., Formulated and evaluated roxithromycin tablets 
employing roxithromycin (ROX) solid dispersions.Dispersions of ROX in mannitol 
by different techniques like physical mixing, melting method, melt solvent method, 
kneading technique and common solvent method. The compressed tablets were 
evaluated for various tablet characteristics including dissolution rate and efficiency. 
Marked increase in the dissolution rate and efficiency was observed with tablets of 
dispersions in comparison to tablets formulated with physical mixtures and 
conventional tablets available commercially. Tablets prepared by dispersion of melt 
method have shown highest dissolution rate. Dissolution of ROX from these tablets 
obeyed first-order kinetics. [44]. 
 Ayman A.et al.., Determined of Certain Macrolide Antibiotics in 
Pharmaceutical Preparations by Spectrophotometrically.A direct colorimetric method 
was described for the rapid, sensitive and accurate determination of certain macrolide 
antibiotics; roxithromycin (ROX), azithromycin (AZM), and clarithromycin (CLM) in 
bulk powder and in pharmaceutical preparations. The proposed method is based on 
reaction of the studied drugs with haematoxylin reagent in the presence of boric acid 
to give a reddish-violet chromogen λmax= 598 nm. [45]. 
Bryskier et al., reviewed of Roxithromycin antimicrobial activity. 
Roxithromycin is a semi-synthetic 14-membered-ring macrolide antibiotic in which 
the Erythronolide A lactone ring has been altered to prevent inactivation in the gastric 
milieu. The In-vitro activity of roxithromycin is well documented and similar to that 
of other macrolide Antibiotics. Roxithromycin is active against Gram-positive and 
Gram-negative cocci, Grampositive bacilli and some Gram-negative bacilli, but has 
no significant effect on the predominant faecal flora. It also displays good activity 
against atypical pathogens Like other macrolides, roxithromycin displays a significant 
postantibiotic effect which is dependent on the pathogens under study, the 
concentration of Roxithromycin and the duration of exposure. In vivo, roxithromycin 
is as effective or more Effective than other macrolides in a wide range of infections. 
[46]. 
Swapna.G et al., discussed about development and validation of new 
analytical Methods for the determination of roxithromycin in Bulk and 
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pharmaceutical formulations by uv-visible Spectrophotometry. In developing these 
methods, a systematic study of the effects of Various relevant parameters in the 
methods concerned were undertaken by varying one parameter at a time and 
controlling all other parameters to get maximum color development, minimum blank 
color, reproducibility and the reasonable period of stability of final colored Species 
formed. [46]. 
Chauhan Vanita et al., formulated an oro dispersible tablet (ODT) of the 
taste-masked Roxithromycin by incorporation of microspheres in the tablets. 
Microspheres of Roxithromycin were prepared by solvent evaporation method. The 
physical properties of prepared microspheres were evaluated with regard to yield, 
drug content, flow properties, particle size, in vitro drug release and taste. The 
average Size of microspheres was found to be satisfactory in terms of the size and size 
distribution. The odts prepared by direct compression method and evaluated for 
hardness, thickness, weight variation, friability, disintegration time, drug content, 
wetting time, in vitro disintegration, in vitro drug release and stability. [47]. 
Ms.Subhasri Mohapatrab et al., were prepared Dispersible tablets of 
Roxithromycin using a superdisintegrant such as Primogel powder, Kollidone 
powder, Crosscaramellose powder , and MCC in different concentration by direct 
compression method. Formulations were evaluated for the standard of dispersible 
tablets . It was observed that all the formulations were acceptable with reasonable 
limits of standard required for dispersible tablets. This study charecterise the most 
effective superdisintegrant. [48]. 
Abhishek Kumar Singh et al., formulated a FDT of the taste-masked 
Roxithromycin by incorporation of Excipients in the tablets. Method of 
Roxithromycin was prepared by solvent evaporation method. The optimized 
combinations were subjected to FT-IR and while dissolution, and accelerated stability 
studies were performed on their formulations. The physical properties were evaluated 
with regard to yield, drug content, flow properties, particle size, in vitro drug release 
and taste. The average size of microspheres was found to be satisfactory in terms of 
the size and size distribution. The fdts Prepared by direct compression method and 
evaluated for hardness, thickness, weight variation, friability, disintegration time, drug 
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content, wetting time, in vitro disintegration, in vitro drug release and stability. Result 
and discussion simulated salivary fluid (ph 6.8) and sufficient flow properties was 
shown in the drug: polymer ratio. [49]. 
Raiyani rushang.c et al., Formulated and evaluated of fast disintegrating 
tablet of roxithromycin. The calibration curve of Roxithromycin was prepared in 
phosphate buffer ph 6.0 follow the beer lamberts law between the different 
Concentration ranges at λmax 205 nm. Formulation parameters like solubility study, 
melting point determination, water content, drug exstudy at different temperature 
were carried out.  Different preformulation excipients interactionout. Data obtained 
from above pre-formulation study concluded that there is no interaction between drug 
and involved excipients in this project study. The tablets were evaluated for thickness, 
hardness, friability, weight variation, wetting time, water absorption, drug content, 
disintegration time and in vitro dissolution studies. [50]. 
Nief Rahman Ahmed et al., developed New spectrophotometric determination 
of roxithromycin in pharmaceutical preparations and environmental samples. A new, 
simple, selective, sensitive and accurate direct spectrophotometric method has been 
developed for the determination of roxithromycin in pure form , pharmaceutical 
preparations and environmental water samples. The method was based on the reaction 
of roxithromycin with concentrated sulfuric acid to form red color product having 
absorption maxima at 485nm. [51]. 
B.N. Suhagia et al., developed Spectrophotometric method for determination of 
roxithromycin in its pharmaceutical dosage forms. In the proposed method, 
roxithromycin is oxidized with potassium permanganate to liberate formaldehyde, 
which is determined in situ using acetyl acetone in the presence of ammonium acetate 
to give a yellow-coloured chromogen with absorption maxima at 412 nm. The method 
is found to be linear in the concentration range of 10-75 μg/ml with regression 
coefficient of 0.9987. [52]. 
Sandhya Bhimrao Lahane et al., developed new Analytical Method for 
Macrolide Antibiotic Macrolide antibiotics, mostly derivatived from erythromycin, 
are a class of antimicrobial compounds widely used against infectious diseases. The 
quantification of macrolide antibiotic in tablet formulation for routine quality control 
 Department of Pharmaceutics  
Arulmigu Kalasalingam College of Pharmacy. Page 22 
 
 
analysis using transmission Fourier Transform Infrared (FT-IR) spectroscopy. A 
number of analytical techniques such as ultraviolet (UV), high performance liquid 
chromatography(HPLC),capillary electrophoresis, various electrochemical detections, 
near infrared (NIR) and liquid chromatography/mass spectrometry (LC/ MS) have 
been applied for the determination and qualitative analysis of macrolide antibiotics in 
raw materials, dosage forms and biological samples. [53]. 
 A.S Mundada et al., Formulation and evaluation of dispersible taste masked 
tablet of roxithromycin. Roxithromycin is a broad spectrum, semisynthetic macrolide 
antibiotic, having bitter taste. The complexes were evaluated for bulk density, angle 
of repose, taste masking, and in vitro drug release. In vitro drug release studies 
showed more than 80% drug release from the optimized formulation within 30 min. 
Amberlite IRP64 was found to be better complexing agent for masking the bitter taste 
of roxithromycin.[54] 
Praveen Kumar et al., A Study on Solubility Enhancement Methods for 
Poorly Water Soluble Drugs. It is generally recognized that poor solubility is one of 
the most frequently encountered difficulties in the field of pharmaceutics. Low 
solubility and subsequent unsatisfactory dissolution rate often compromise oral 
bioavailability. However, poorly water-soluble drugs, when administered orally, have 
been shown to be slowly and unpredictably absorbed since their bioavailability is 
largely dependent on the dissolution process in gastrointestinal tract. This article 
demonstrates the various methods used to increase dissolution rates, preparation 
techniques of solid dispersion, and characterization methods of the solid 
dispersion.[55] 
C.M Bhaskar Reddy et al., developed UV spectrophotometric method for the 
estimation of Roxithromycin in bulk and tablet dosage form. Roxithromycin shows 
maximum absorbance at 420nm in presence of solvent Deionised Water and 
phosphate buffer of ph 7.4. The Beer’s law is obeyed in the concentration range of 20-
70 μg/ ml for this drug. The graph of the drug shows a straight line with correlation 
coefficient of 0 .9840. The assay method of the drug was validated by accuracy and 
precision of the proposed method. The results are validated as per the directions of 
International conference on Harmonization.[56] 
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G. V Subbareddy et al.,Development, validation and application of UV 
spectrophotometric method for the determination of roxithromycin in bulk and 
pharmaceutical dosage form.  Roxithromycin is a semi-synthetic macrolide antibiotic. 
It is used to treat respiratory tract, urinary and soft tissue infections. The present 
research work discussed the development of a simple, sensitive, rapid, accurate, 
precise and economical UV Spectrophotometric method for the evaluation of 
Roxithromycin in bulk and pharmaceutical dosage form which is based on the 
measurement of absorption maxima at 420 nm.[57] 
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AIM AND OBJECTIVE 
 
AIM OF THE STUDY: 
  Roxithromycin is a BCS Class II /IV drug belonging to macrolide antibiotic 
used in the treatment of a broad variety of infections, of which respiratory tract 
infections are the primary indication. But Roxithromycin has only 50% oral 
bioavailability, due to its poor aqueous solubility, which limits its potential for 
optimal drug delivery and therapeutic effect. Its poor solubility is thus an obstacle in 
formulation development. 
So it is more cost effective to chemically re-design a molecule than to move 
through the whole development process, it is crucial to develop a formulation that 
overcomes problems of insolubility. The  aim of this study to enhance the solubility of 
Roxithromycin by using its solvates. 
 
OBJECTIVE OF THE STUDY: 
The objectives of this study to enhance the solubility and Dissolution by 
• To Prepare Roxithromycin solvates using Choloroform and Ethanol as 
solvents 
• To characterise the different forms prepared; 
• To evaluate the Solvated form forms on their solubility and Dissolution 
• To find the suitability of Solvated form in Pharmaceutical Formulation.  
                    
                    
 
 
 
 
PLAN OF WORK 
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PLAN OF WORK 
 
The present work carried out to solubility and dissolution enhancement of 
roxithromycin which is having low bioavailability due to its poor aqueous solubility. 
So study was carried out to enhance the Solubility and dissolution of Roxithromycin 
in the following steps 
 
1. Literature survey 
2. Procurement of drug and Chemicals 
3. Preformulation of Roxithromycin 
4. Preparation of Roxithromycin Solvates 
5. Characterisation of Roxithromycin Solvates 
6. Formulation of Roxithromycin Solvates 
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MATERIALS AND METHODS 
 
LIST OF EQUIPMENTS: 
 
S.NO 
 
NAME OF EQUIPMENTS 
 
MANUFACTURER 
01. Digital balance SHIMADZC ELB 300 
02. UV- visible spectrometer SHIMADZC UV -1700 
03. FTIR SHIMADZU 
04. XRD BRUKER ECO D8 
05. SEM Analyser ZEISS-5200 SEM 
06. Hot air oven ELCON 
07. Magnetic stirrer REMI 
08. Dissolution Apparatus LABINDIA 
09. Disintegration apparatus INCO 
10. Tablet Punching Machine REMEK 
11. Hardness Tester PFIZER 
12 Friability Apparatus INCO 
Table no:4 
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LIST OF MATERIALS 
 
S.NO MATERIALS MANUFACTURER 
01. 
 Roxthiromycin GIFT sample from Madras Pharmaceuticals 
02. Ethanol Sisco research laboratory 
03. Chloroform Sisco research laboratory 
04. Microcrystalline Cellulose GIFT sample from Microlabs 
05. Talc Sd fine Chemicals,Mumbai 
06. Sodium Starch Glycolate Sd fine Chemicals,Mumbai 
07. Magnesium Sterate GIFT sample from Microlabs 
Table no:5 
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DRUG PROFILE 
 
 ROXITHROMYCIN[58]: 
  Roxithromycin is a semi-synthetic macrolide antibiotic. It is used to treat 
respiratory tract, urinary and soft tissue infections. Roxithromycin is derived from 
erythromycin, containing the same 14-membered lactone ring.  
It acts on gram-positive bacteria and gram-negative bacteria.  It is used to treat 
respiratory tract, urinary and soft tissue infections. Roxithromycin is derived from 
erythromycin, containing the same 14-membered lactone ring. However, an N-oxime 
side chain is attached to the lactone ring. It is also currently undergoing clinical trials 
for the treatment of male-pattern hair loss.  
Roxithromycin is available under several brandnames, for example, Xthrocin, 
Roxl-150, Roxo, Surlid, Rulide, Biaxsig, Roxar, Roximycin, Roxomycin, Rulid, 
Tirabicin and Coroxin. Roxithromycin is not available in the United States. 
Roxithromycin has also been tested to possess antimalarial activity. 
  Roxithromycin prevents bacteria from growing, by interfering with their 
protein synthesis. Roxithromycin binds to the subunit 50S of the bacterial ribosome, 
and thus inhibits the translocation of peptides. Roxithromycin has similar 
antimicrobial spectrum as erythromycin, but is more effective against certain gram-
negative bacteria, particularly Legionella pneumophila Roxithromycin has fewer 
interactions than erythromycin as it has a lower affinity for cytochrome P450 
Roxithromycin does not interact with hormonal contraceptives, prednisolone, 
carbamazepine, ranitidine or antacids.  
Rroxithromcin is 150 mg twice in a day, 30 minutes before meals or 2 hours 
after. For children, it is 2.5 - 5.0 mg/kg of body weight, given in two divided doses 
per day. 
It is used in respiratory tract infections like pharyngitis, pneumonia, chronic 
bronchitis and bronchopneumonia. 
Chemical names: (3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R)-4-[(2,6-
dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-
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Administration: 
 Should be taken on an empty stomach. Take at least 15 min before meals. 
Pharmacodynamics: 
Macrolides are considered time-dependent antibiotics. 
Pharmacokinetics: 
Cmax: 6.8mg/L 
 Half- life: 8-13 hours 
 Bioavailability: 72-85% 
Adverse Effects: 
 Gastrointestinal: abdominal cramps, nausea, diarrhea, anorexia, 
pancreatitis 
 Genitourinary: vulvovaginal candidiasis, renal failure 
 Cardiovascular System: prolongation of QT interval 
 Hepatic: hepatotoxicity, jaundice 
 Hematologic: eosinophilia, thrombocytosis, lymphopenia 
 Central Nervous System: headache, fatigue 
 Endocrine/Metabolic: hyperglycemia 
 Dermatologic: itching, nail discoloratiom 
Warnings and precautions :  
Caution should be exercised in patients with history of liver impairment, 
abnormal heart rhythm, any allergy, who are taking other medications, during 
pregnancyand breastfeeding.  Monitor liver function regularly while taking this 
medication.  
Avoid long-term use of this medication; otherwise it may cause liver damage.  
Other Precautions :  
Avoid excess dosage.  
Storage Conditions :  
Store it at room temperature. 
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Uses: 
 acute pharyngitis (sore throat and discomfort when swallowing) 
 tonsillitis. 
 sinusitis. 
 acute bronchitis (infection of the bronchi causing coughing) 
 pneumonia (lung infection characterised by fever, malaise, headache). 
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Synonyms : 
Carboxymethyl starch, sodium salt; carboxymethylamylum natricum; 
Explosol; Explotab; Glycolys; Primojel; starch carboxymethyl ether, sodium salt. 
Chemical Name: 
 Sodium carboxymethyl starch 
Description : 
Sodium starch glycolate is a white or almost white free-flowing very 
hygroscopic powder 
Melting point: 
 Does not melt, but chars at approximately 2008C. 
Functional Category: 
 Tablet and capsule disintegrant. 
 
TALC [59] 
Talc is a clay mineral composed of hydrated magnesium silicate. Naturally 
occuring form of hydrous magnesium silicate containing varying proportions of such 
associated minerals as alpha-quartz, calcite, chlorite, dolomite, kaolin, magnesite, and 
phlogopite. Talc derived from deposits that are known to contain associated asbestos 
is not food grade.  
Formula:  H2Mg3(SiO3)4 or Mg3Si4O10(OH)2.  
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Thermal Behaviour:  
             Stable to about 900° Celsius. 
Health Risks: 
            talcum powders may have small amounts of amphibole contamination. 
Industrial Uses: 
           Filler in paints, rubber. In cosmetics and as a lubricating dusting powder. 
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PREPARATION OF REAGENTS AND SOLUTION 
 
PREPARATION OF 0.1N HCl : 
 8.5ml of hydrochloric acid and add with 1000 ml of water is makeup 
volumetric flask.ee 
PREPARATION OF PHOSPHATE BUFFER pH 6: 
 6.8 gm potassium dihydrogen phosphate  and 1000ml of water adjust the pH 6 
by using sodium hydroxide. 
 
PREPARATION OF STANDARD STOCK SOLUTION AND CALIBRATION 
CURVE:  
Standard stock solution prepared by 10 mg of Roxithromycin as dissolving  in 
10 ml of 0.1N HCL in volumetric flask than further 1 ml is dissolved in 100 ml to get 
concentration of 10μg/ml. The aliquots of 0.5 to 3 ml of standard stock solution were 
transferred into series of 10ml volumetric flask and made up to mark with 0.1N HCL 
to reach the concentration range of 0.5μg/ml to 3μg/ml respectively. A graph of 
absorbance versus concentration of the solution was recorded with help of UV 
spectrophotometer at 205nm.  
 
  Table no: 6 CALIBRATION CURVE OF ROXITHROMYCIN 
S.NO CONCENTRATION (μg/ml) ABSORBANCE 
01. 0.5 0.106 
02. 1 0.210 
03. 1.5 0.312 
04. 2 0.405 
05. 2.5 0.5 
06. 3 0.589 
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Calibration Curve of Roxitromycin 
 
 
Figure No:11 
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Physical Characteristics of  Drug: 
Solubility Studies: 
100 mg of Roxithromycin dissolved in  100 ml of each distilled water ,0.1 N 
HCI and phosphate buffer (pH 6) in a separate beaker and kept it in a magnetic stirrer 
at 50 rpm for 24 hours in room temperature. After 24 hours the concentration of the 
filtered Samples were determined spectro photometrically at 205 nm at UV visible 
Spectrophotometer. The Procedure was repeated at three times. The Solubility results 
were tabulated based on the % concentration of drugs soluble in the given solvent 
given below 
% Concentration of 
Drug in given solution Distilled water 0.1 N Hcl 
Phosphate Buffer 
pH 6 
1  Test 8.1 32.12 67.85 
2 Test 7.23 41.17 69.12 
3 Test 7.45 40.82 69.3 
Average 7.59 38.03 68.75 
            Table no 7: Determination of bulk density and tapped density  
An accurately weighed quantity of the powder (W) was carefully poured into 
the graduated cylinder and the volume (Vo) was measured. Then the graduated 
cylinder was closed with lid, set into the density determination apparatus (bulk 
density apparatus). The density apparatus was set for 100 taps and after that, the 
volume (Vf) was measured and continued operation till the two consecutive readings 
were equal. The bulk density, and tapped density were calculated using the following 
formulas  
Bulk density = W / Vo 
Tapped density = W / Vf 
Where, W = weight of the powder,  
VO = initial volume 
Vf  = final volume 
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Compressibility index 
 Compressibility index is an important measure that can be obtained from the 
bulk and tapped densities. In theory, the less compressible a material the more 
flowable it is. A material having values of less than 20 to 30% is defined as the free 
flowing material. 
   CI   =   100 (Vo – Vf) 
                                                    V0 
Hausner’s ratio  
The hausner’s ratio is the ratio between tapped density to bulk density. It 
indicates the value for flowability.If the value less than 1.25 flows is excellent. If the 
value is greater than 1.25 it indicates poor flow. It requires 0.2%w/w of Glidant to 
improve the flowability. 
Hausner’s Ratio = Tapped Density / Bulk Density 
Angle of Repose:  
 Angle of Repose (Φ) is the maximum angle between the surface of a pile of 
powder and horizontal plane. It is usually determined by Fixed Funnel Method and is 
the measure of the flowability of powder/granules. 
 Φ = tan-1 (h / r)  
Where,  
h = height of heap of pile r = radius of base of pile           
   Table no 8: angle of repose and flow property of powder drug 
S.NO Angle Of Repose  Flow Property  
1. Less than 25˚  Excellent flow  
2. 25˚ to 30˚  Good  
3. 30˚ to 40˚  Possible flow  
4. greater than 40˚  Very poor  
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LOSS ON DRYING 
Place the bottle in the  oven, remove the stopper (placing it nearby), dry under 
the specified conditions, stopper again, take the bottle out of the oven, and weigh it 
again. If heated, unless otherwise specified, allow to cool it in desiccators, and weigh 
it accurately. If the powder melts at a temperature lower than the specified drying 
temperature, dry it at a temperature 105 °C ± 2 °C lower than the melting temperature 
for 1 to 2 hours, and dry it under the specified conditions.  
 
Loss on drying = Initial weight of the drug – Final weight of the drug X 100 
    Initial weight of the drug 
Sl.No Parameters Roxithromycin 
1.  Bulk density (g/ml) 0.3844 
2.  Tap density (g/ml) 0.4908 
3.  Compressibility Index 21.67 
4.  Hausner’s Ratio 1.2767 
5.  Angle of repose(°) 36 
6.  Loss on drying (%) 2.2 
  Table no:9 Physical parameter of Roxithromycin 
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Preparation of Roxithromycin Solvates: 
The solvate of roxithromycin was prepared by recrystallization of the raw 
material from Solvent (Chloroform ,Ethanol ). Approximately  5 g of roxithromycin 
was added to 50 mL of Solvent while stirring continuously and heating the solution to 
approximately 60°C in a magnetic stirrer for 4 hours. After slow evaporation of the 
Solvent, a dense mass was obtained.  This mass was dry but tend to stick to the 
surfaces of containers. The desolvated solid was prepared by placing the 
Roxithromycin solvate in a  Dessicator at room temperature for 48 hrs. Then it was 
triturated and stored in airtight container. 
 
Material Formulation Code 
Roxithromycin F 1 
Roxithromycin Choloroform Solvate F2 
Roxithromycin Ethanol Solvate F 3 
              
Table No10: Formulation Code for Roxithromycin Solvate 
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Aqueous Solubility Studies: 
Aqueous solubility studies were carried out by adding excess of drug ( 
F1,F2,F3) 100 mg in 100 ml of distilled water .They were were continuously stirred 
on an electromagnetic stirrer with  at 37 °C and 100 rpm for 48 hrs. Then filtered 
,suitably diluted and analyzed, spectrophotometrically (UV-1700, UV/Vis 
spectrophotometer, Shimadzu, Japan), for the dissolved drug at 205 nm.  
            Table no12: Aqueous solubility studies 
S.No 
µg/ml in solution 
F1 F2 F3 
1 1.08 6.38 5.12 
 
DISSOLUTION STUDIES: 
In-vitro Dissolution studies were performed using USP Type II dissolution 
paddle apparatus. Accurately  weighed  amount 100mg of  samples( F1,F2,F3) 
was  taken  for  dissolution studies. The dissolution test was performed using 900 ml  
using   pH 1.2 0.1 N Hcl at 37 ± 0.5°C. The speed of rotation of paddle was set at 75 
rpm. The dissolution tests were carried out with sampling time intervals of 5, 15, 30, 
45, and 60 min respectively. The samples were analyzed using a double beam UV-
spectrophotometer and the absorbance was recorded at 205 nm. The in-vitro 
dissolution studies were tabulated. 
                           Table no12: dissolution studies 
S.No Time in Minutes %  Drug Release F1 F2 F3 
1 5 min 8.12 21.78 22.18 
2 15 min 20.35 34.57 33.42 
3 30 min 24.12 43.76 39.72 
4 45 min 32.83 59.58 54.27 
5 60 min 38.57 76.14 68.12 
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FORMULATION OF TABLETS 
The Roxithromycin Tablets were prepared by Direct Compression method per 
the given formula in Table  
Formulation  
Stage-1: The Roxithromycin Powder was sifted through 40 # mesh.  
Stage-2: All the materials required as per the formulae were blended in a 
closed polyethylene bag and mixed well. 
 Stage-3: The blends were sifted through 20# mesh. 
Stage-4: The lubrication materials Starch talc, and magnesium stearate were 
sifted through 40# mesh and added into the sifted granules and lubricated.  
Stage -5: The blend is compressed into tablets by using Rotary tablet 
compression machine After the compression of tablets were tested for physical 
parameters. 
Table no13: Formulation of Tablet 
Ingredients F4 F5 F6 
Roxithromycin  75 mg 75 mg 75 mg 
Micro crystalline 
Cellulose 
110 mg 110 mg 110 mg 
Sodium Starch 
Glycolate 
15 mg 15 mg 15 mg 
Talc 4 mg 4mg 4 mg 
 Magnesium Sterate 1 mg 1 mg 1 mg 
 
                 F4-Pure Drug 
                 F5- Choloroform Solvate (Fresh Solvate) 
                 F6 –Choloroform Solvate (3 months Old) 
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EVALUATION OF FABRICATED TABLETS: 
Physical characteristics of formulated tablets were evaluated for tablet size, 
hardness, friability, and weight variation. 
Hardness: 
The hardness of the tablet was tested by using Pfizer hardness tester. The 
results was shown in Table No-  
Friability:  
It was done in Electro lab friabilator apparatus where the tablets were 
subjected to the combined effect of abrasion and shock by utilizing a plastic chamber 
that revolves at 25rpm dropping the tablets at a distance of six inches with each 
revolution. Preweighed samples of 20 tablets were placed in the friabilator, which is 
then operated for 100 revolutions. The tablets are then dusted and reweighed. 
Conventional compressed tablets that lose less than 0.5 to 1.0 of their weight as 
generally considered acceptable. The results were shown in Table No-12. 
                          W1-W2 
Friability = -----------------x100 
                                W1 
Weight Variation Test                                                      
Twenty tablets were randomly selected form each batch and individually 
weighed. The average weight and standard deviation of 20 tablets was calculated. The 
batch passes the test for weight variation test if not more then two of the individual 
tablet weight deviate from the average weight by more than the percentage shown in 
Table, and none deviate by more than twice the percentage shown. The results were 
shown in Table. 
Table No.14 Weight Variation Tolerance for Tablet (USP)  
Percentage deviation allowed under weight variation test. 
Average weight of tablet (X mg) Percentage deviation 
X < 130 mg 
130 < X < 324 mg 
X > 324 mg 
10 
7.5 
5 
Percentage deviation allowed under weight variation test. 
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The observations of weight variation test of each batch are shown in Table No: 
15. 
Disintegration Test: 
The tablets were taken in a rigid basket rack assembly supporting six 
cylindrical glass tubes.  The assembly was suspended in the liquid medium in a 1000 
ml beaker.  The volume of liquid was such that, wire mesh at its lower point was at 25 
mm below the surface of the liquid and its lower point was at 25 mm above the 
bottom of the beaker. A temperature was maintain at 37±20C.  Finally the average 
disintegration time was recorded. 
The value of the disintegration time of all the batches given in the Table No-
15 
Drug content Uniformity: 
 5 tablets were powdered and powder equivalent to 75mg of drug was weighed 
and taken in a 50ml volumetric flask volume was made with Phosphate Buffer pH 6.0. 
The filtered using 0.2 µ membrane filter. From filtrate, 10 ml of solution was pipette 
out and diluted up to 100 ml with the phosphate buffer pH 6.0, and absorbance was 
measured at 205 nm using UV double beam spectrophotometer 
The value of the disintegration time of all the batches given in the Table No-15 
 
Table No:15 EVALUATION OF FABRICATED TABLETS: 
Formulation 
code 
Disintegration
Time 
(in minutes) 
Hardness 
Kg/Cm2 
Weight 
Variation
Friability 
(%w/w) 
% 
Drug 
Content
F4          4.00 4.5 199 0.12 97.25  
F5 4.23 4.2 203 0.16 98.13 
F6 4.12 4.0 200 0.13 96.54 
 
  
 Department of Pharmaceutics  
Arulmigu Kalasalingam College of Pharmacy. Page 58 
 
 
IN-VITRO DRUG RELEASE  
In-vitro drug release study was performed using type 1 of IP (paddle) at a 
speed of 100 rpm. The medium was Phosphate buffer 6 (900 ml) maintained at 
37oC±0.5oC. The dissolution test was conducted for 45 minutes; samples of 5 ml were 
withdrawn in the interval of 10,20,30,45 minutes with replacement of equal volume of 
dissolution medium. The withdrawn samples were filtered and the concentration of 
Roxithromycin was measured by determining absorbance at 205 nm using UV 
spectrophotometer. 
 
S.No Time in Minutes 
%  Drug Release 
F4 F5 F6 
1 10 min 25.49 31.57 24.28 
2 20 min 39.83 47.49 35.61 
3 30 min 50.52 61.25 49.85 
4 45 min 62.75 76.58 64.31 
5 60 min 72.08 88.14 71.25 
                    Table No16: IN-VITRO DRUG RELEASE 
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Preformulation Studies of Roxithromycin: 
Bulk density, tap density, obtained bulk density and tap density values, loss on 
drying, compressibility index was calculated. The drugare poor flow and low 
compressibility. Good flow of powder /granules is essential in tableting because the 
flow property and compressibility is likely to influence the compression process in the 
preparation of tablets. The moisture content has influence on solubility & Formulation 
process in various aspects like sticking and also affects the moisture sensitivity drugs. 
The LOD for Roxithromycin was 2.2 %. 
Preparation of Roxithromycin Solvates: 
Roxithromycin  is poorly water soluble and an improvement in its solubility 
could result in an improvement in its bioavailability .So solvates of roxithromycin 
was prepared by recrystallization by using  Chloroform (F2), Ethanol (F3) as solvents. 
Characterization of Roxithromycin Solvates: 
FTIR STUDIES: 
Overlapping of F1, F2,F3 FTIR Spectra didn’t show much variation in the 
FTIR spectra of solvated Roxithromycin ( F2 ,F3) compared to Roxitromycin (F1).So 
It revealed that that solvates didn’t cause much variation in Chemical Structure of 
Pure Drug. 
 
Figure no. 24. Comparative FTIR Spectra 
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X-ray powder diffraction (XRPD) STUDIES: 
X-ray patterns of the Roxithromycin ( F 1), chloroform solvate (F2) & Ethanol 
solvate (F 3)  showed deviation in the peak heights , it is suggested that the  solvated 
drug showed less crystalline compared to pure drug which is indicated by reduction in 
peak heights .In addition, on the X-ray diffraction pattern of the chloroform solvate 
resembles that of the amorphous solid. These results show the Reduction in crystalline 
of solvated drugs compared to roxithromycin Drug. Superimposed XRPD 
diffractograms are shown in given figure. 
 
 
Figure no. 25. Comparative XPRD diffractogram 
 
  
0
2000
4000
6000
8000
10000
12000
14000
16000
0 20 40 60 80 100 120
C
o
u
n
t
s
 
2 THETA 
XPRD OF F1,F2,F3 
F1
F2
F3
 Departmen
Arulmigu K
 
 
SEM Anal
SEM
roxithromy
with more 
smooth sur
was shown 
SEM of 
Aqueous S
Aqu
of Roxithr
compared 
following o
t of Pharma
alasalingam
ysis: [SCA
 microsco
cin, It was 
crystalline 
face and Et
in given Fi
Roxithromy
olubility St
eous solub
omycin. T
to pure dr
rder. 
Figure
ceutics  
 College o
NNING EL
py images
found that 
structure c
hanol  solv
gure. 
cin S
 
Figu
udies: 
ility studies
he chloro
ug and eth
no. 27. Aq
1.0
0
1
2
3
4
5
6
7
F1
Aqeou
f Pharmacy
ECTRON
 of the so
 the Roxith
ompared to
ate (F 3) w
EM of Chlo
Solvat
re no. 26. 
 indicated 
form solva
anol solva
F1 < F3 
ueous Solu
8 
s Solub
.
 MICROS
lvates wer
romycin( F
 Chlorofor
hich has a
roform 
e 
Comparati
that solvate
tes showe
te. The aq
< F2 
bility Stud
6.38 
F2
ility Stu
COPE] 
e compared
1)  has a 
m solvate 
 partial sm
SEM of 
ve SEM 
s has  incre
d better a
ueous solu
ies of Solv
5.12 
F3
dies 
 with that
striated app
(F 2) whic
ooth surfac
Ethanol So
ased  the so
queous so
bility was
 
ates  
Page 62 
 of the 
earance 
h has a 
e which 
lvate 
lubility 
lubility 
 in the 
 Department of Pharmaceutics  
Arulmigu Kalasalingam College of Pharmacy. Page 63 
 
 
Dissolution Studies: 
The Chloroform solvate( F2)  showed better in vitro release profile compared 
to Pure Drug (F1) and Ethanol Solvate ( F3).The Pure Drug showed a release of  38% 
release in 60 minutes. But solvates showed enhanced dissolution properties compared 
to pure drug may be due to reduction in crystalline nature of drug during salvation. 
The invitro release was in the following order. 
F1 < F3 < F2 
 
Figure no. 28. Invitro Release Profile  of Solvates  
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CONCLUSION 
 
According to recent estimates, nearly 40% of new chemical entities are 
rejected because of poor solubility i.e. biopharmaceutical properties. Poor Solubility 
of drug  may result in inadequate bioavailability and thus in ineffective treatment 
regimes. Similarly, roxithromycin also has a poor solubility profile and the form 
available on the market is mostly the stable, crystalline monohydrate with the oral 
bioavailability 50%.So the Objective of the present study to enhance the solubility 
and dissolution of Roxithromycin using solvates. Two solvate forms of roxithromycin 
were prepared by recrystallisation using  chloroform and ethanol solvents. It was 
found that the Solvates showed better solubility and dissolution profile compared to 
Roxithromycin.Among Solvate Choloroform solvate showed better solubility and 
Dissolution profile than Ethanol solvate. 
The tablets of Choloroform solvates were formulated by direct compression 
method to find the suitability of Solvates in the formulation of Pharmaceutical Dosage 
form by comparing Freshly Prepared Choloroform Solvates against 3 months old 
choloroform solvate .The variants of solvates were used to find out the stability of 
solvates.Based on the evaluation of tablets it was found that During storage the 
solvates transformed in to more crystalline substance which may affect dissolution 
profile from the dosage. 
From the study it was concluded that Solvates can be used to enhance the 
solubility and dissolution of Poorly soluble drugs. 
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FUTURE PLAN 
Solvates  may be further investigated for following studies, 
• Stability Studies. 
• Toxicity studies 
• Scale-up studies of optimized formulations 
• Bioavailability studies. 
• Studies of different drug candidates and their evaluation. 
• In-vivo and In-vitro correlation 
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